Scientists in the Sunwoo Lab at Stanford have discovered that inhibition of the histone lysine demethylase KDMA2 can enhance the efficacy of immune checkpoint blockade therapies, like anti-PD-1.
Researchers in the Sunwoo Lab have developed a method to differentiate intra-epithelial innate lymphoid cells type 1 (ieILC1s) from conventional peripheral natural kills cells for immunotherapeutic purposes.